Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells

BACKGROUND: Chimeric antigen receptor (CAR)–modified T cells that target the CD19 antigen present a novel promising therapy for the treatment of relapsed B-cell acute lymphoblastic leukemia (B-ALL). Although cytokine release syndrome (CRS) and neurotoxicity have emerged as predominant noninfectious...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jae H, Romero, F Andres, Taur, Ying, Sadelain, Michel, Brentjens, Renier J, Hohl, Tobias M, Seo, Susan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070095/
https://www.ncbi.nlm.nih.gov/pubmed/29481659
http://dx.doi.org/10.1093/cid/ciy152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070095/
https://www.ncbi.nlm.nih.gov/pubmed/29481659
http://dx.doi.org/10.1093/cid/ciy152

Ejemplares similares